Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors
| Autor: | Sandra Claes, Adriaan Vanderstichele, A.S. Van Rompuy, T Van Gorp, Jaak Billen, Jolien Ceusters, Gitte Thirion, Ignace Vergote, Dirk Timmerman, Thaïs Baert, An Coosemans, J. Oosterlynck, Wouter Froyman, A Van Hoylandt, R. Heremans, Tom Bourne, Dominique Schols, E.T.L. Achten, B. Van Calster, Chiara Landolfo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
0301 basic medicine Oncology medicine.medical_specialty Adolescent Malignancy Logistic regression Adnexal mass Diagnosis Differential Young Adult 03 medical and health sciences WAP Four-Disulfide Core Domain Protein 2 0302 clinical medicine Internal medicine Humans Medicine Antigens Tumor-Associated Carbohydrate Prospective Studies Stage (cooking) Aged Neoplasm Staging Aged 80 and over Ovarian Neoplasms Receiver operating characteristic business.industry Ovary Membrane Proteins Obstetrics and Gynecology Middle Aged medicine.disease Confidence interval 030104 developmental biology ROC Curve CA-125 Antigen 030220 oncology & carcinogenesis Preoperative Period Female Differential diagnosis business Ovarian cancer |
| Zdroj: | Gynecologic Oncology. 159:811-819 |
| ISSN: | 0090-8258 |
| Popis: | Objective To estimate the diagnostic value of tumor and immune related proteins in the discrimination between benign and malignant adnexal masses, and between different subgroups of tumors. Methods In this exploratory diagnostic study, 254 patients with an adnexal mass scheduled for surgery were consecutively enrolled at the University Hospitals Leuven (128 benign, 42 borderline, 22 stage I, 55 stage II-IV, and 7 secondary metastatic tumors). The quantification of 33 serum proteins was done preoperatively, using multiplex high throughput immunoassays (Luminex) and electrochemiluminescence immuno-assay (ECLIA). We calculated univariable areas under the Receiver Operating Characteristic Curves (AUCs). To discriminate malignant from benign tumors, multivariable ridge logistic regression with backward elimination was performed, using bootstrapping to validate the resulting AUCs. Results CA125 had the highest univariable AUC to discriminate malignant from benign tumors (0.85, 95% confidence interval 0.79-0.89). Combining CA125 with CA72.4 and HE4 increased the AUC to 0.87. For benign vs borderline tumors, CA125 had the highest univariable AUC (0.74). For borderline vs stage I malignancy, no proteins were promising. For stage I vs II-IV malignancy, CA125, HE4, CA72.4, CA15.3 and LAP had univariable AUCs ≥0.80. Conclusions The results confirm the dominant role of CA125 for identifying malignancy, and suggest that other markers (HE4, CA72.4, CA15.3 and LAP) may help to distinguish between stage I and stage II-IV malignancies. However, further research is needed, also to investigate the added value over clinical and ultrasound predictors of malignancy, focusing on the differentiation between subtypes of malignancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect